stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) EV/FCF
As of 6 November 2026, BioMarin Pharmaceutical Inc. (BMRN) trades at a EV/FCF of 26.2×. Over the past ten years it has ranged from −269× (December 2019) to 7,129× (June 2020); the current reading is higher than 48% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 15.2× | (40.53%) |
| FY2024 | 25.6× | (92.82%) |
| FY2023 | 357× | 185.78% |
| FY2022 | 125× | 42.57% |
| FY2021 | 87.6× | (91.72%) |
| FY2020 | 1,058× | — |
| FY2019 | −169× | — |
| FY2018 | 300× | (56.31%) |
| FY2017 | 688× | — |
| FY2016 | −40.2× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 27.6× | 39.35% |
| Jun 2026 | 19.8× | 42.39% |
| Mar 2026 | 13.9× | (8.59%) |
| Dec 2025 | 15.2× | 25.70% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| TWST Twist Bioscience Corporation compare | −77.9× |
| KYMR Kymera Therapeutics, Inc. compare | −40.2× |
| IBRX ImmunityBio, Inc. compare | −32.5× |
| SMMT Summit Therapeutics PLC compare | −23.1× |
| PCVX Vaxcyte, Inc. compare | −8.4× |
| BMRN BioMarin Pharmaceutical Inc. | 26.3× |
| TECH Bio-Techne Corp compare | 42.9× |
| CAI Caris Life Sciences,�Inc. compare | 181× |
| TGTX TG Therapeutics, Inc. compare | 485× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on BMRN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement